{"id":790855,"date":"2024-11-26T09:33:24","date_gmt":"2024-11-26T14:33:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/"},"modified":"2024-11-26T09:33:24","modified_gmt":"2024-11-26T14:33:24","slug":"vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/","title":{"rendered":"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs"},"content":{"rendered":"

<\/p>\n

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs<\/b><\/p>\n

SAN FRANCISCO–(BUSINESS WIRE<\/a>)–
\nVir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of HER2-expressing solid tumors and VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC) along with updates on the PRO-XTEN\u2122 platform on January 8, 2025, at 5:00 a.m. PT \/ 8:00 a.m. ET.<\/p>\n

\nA live webcast will be available on https:\/\/investors.vir.bio\/<\/a> and will be archived on www.vir.bio<\/a> for 30 days.<\/p>\n

About Vir Biotechnology, Inc.<\/b><\/p>\n

\nVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and programs across several clinically validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.<\/p>\n

\nVir Biotechnology has exclusive rights to the PRO-XTEN\u2122 masking platform for oncology and infectious disease. PRO-XTEN\u2122 is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201cshould,\u201d \u201ccould,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201caim,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cpromising\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir\u2019s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir\u2019s strategy and plans; Vir\u2019s ability to realize the anticipated benefits from the exclusive worldwide license agreement with Sanofi; difficulties or unanticipated expenses in connection with the agreement, and the potential effects on Vir\u2019s earnings; the risk that Vir\u2019s investment in connection with the agreement will lose value for any number of reasons; the ability of the parties to initiate, progress or complete clinical studies within currently anticipated timelines or at all, and the possibility of unfavorable results from studies, including those involving VIR-5818 and VIR-5500, and any additional programs that may become subject to the agreement; the potential clinical effects, potential benefits, safety and efficacy of the investigational products that are the subject of these programs; data from ongoing studies evaluating such investigational products and programs; Vir\u2019s ability to file applications for regulatory approval or receive regulatory approvals in a timely manner or at all for such investigational products and programs, and the risk that any such approvals may be subject to significant limitations on use; the possibility that the agreement may be terminated for any number of reasons, or that development of the investigational products and programs subject to the agreement may be discontinued, and therefore may never be successfully commercialized; Vir\u2019s ability to successfully commercialize any approved drug products resulting from the agreement; and any assumptions underlying any of the foregoing. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical studies or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; successful development and\/or commercialization of alternative product candidates by Vir\u2019s competitors; changes in expected or existing competition; delays in or disruptions to Vir\u2019s business or clinical studies due to geopolitical changes or other external factors; failure to achieve any necessary regulatory approvals; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir\u2019s filings with the U.S. Securities and Exchange Commission, including the section titled \u201cRisk Factors\u201d contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20241126243740\/en\/<\/a><\/span><\/p>\n

Media
\n<\/b>
Arran Attridge
\n
Senior Vice President, Corporate Communications
\n
aattridge@vir.bio<\/a><\/p>\n

Investors
\n<\/b>
Richard Lepke
\n
Senior Director, Investor Relations
\n
rlepke@vir.bio<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Infectious Diseases Clinical Trials Biotechnology Health Pharmaceutical General Health Science Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs SAN FRANCISCO–(BUSINESS WIRE)– Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of HER2-expressing solid tumors and VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC) along with updates on the PRO-XTEN\u2122 platform on January 8, 2025, at 5:00 a.m. PT \/ 8:00 a.m. ET. A live webcast will be available on https:\/\/investors.vir.bio\/ and will be archived on www.vir.bio for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines … <\/p>\n

Continue reading “Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-790855","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs SAN FRANCISCO–(BUSINESS WIRE)– Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of HER2-expressing solid tumors and VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC) along with updates on the PRO-XTEN\u2122 platform on January 8, 2025, at 5:00 a.m. PT \/ 8:00 a.m. ET. A live webcast will be available on https:\/\/investors.vir.bio\/ and will be archived on www.vir.bio for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines … Continue reading "Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-26T14:33:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241126243740r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs\",\"datePublished\":\"2024-11-26T14:33:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/\"},\"wordCount\":843,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20241126243740r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/\",\"name\":\"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20241126243740r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2024-11-26T14:33:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20241126243740r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20241126243740r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/","og_locale":"en_US","og_type":"article","og_title":"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs - Market Newsdesk","og_description":"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs SAN FRANCISCO–(BUSINESS WIRE)– Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of HER2-expressing solid tumors and VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC) along with updates on the PRO-XTEN\u2122 platform on January 8, 2025, at 5:00 a.m. PT \/ 8:00 a.m. ET. A live webcast will be available on https:\/\/investors.vir.bio\/ and will be archived on www.vir.bio for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines … Continue reading \"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/","og_site_name":"Market Newsdesk","article_published_time":"2024-11-26T14:33:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241126243740r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs","datePublished":"2024-11-26T14:33:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/"},"wordCount":843,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241126243740r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/","name":"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241126243740r1&sid=flmnd&distro=nx&lang=en","datePublished":"2024-11-26T14:33:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241126243740r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20241126243740r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-host-virtual-investor-event-on-pro-xten-masked-t-cell-engager-programs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN\u2122 Masked T-Cell Engager Programs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/790855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=790855"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/790855\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=790855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=790855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=790855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}